SCHEMBL20122801

SCHEMBL20122801

COc1ccc(-c2cc(Cl)cc3c2[nH]c2c(C(F)(F)F)nccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.58
ENPP1 P22413 2/20 0.41
ENPP3 O14638 1/20 0.40
CYP19A1 P11511 2/20 0.40
NT5E P21589 1/20 0.40
GCGR P47871 1/20 0.38
MAPK14 Q16539 1/20 0.38
CHUK O15111 1/20 0.38
ICOSLG O75144 1/20 0.38
ICOS Q9Y6W8 1/20 0.38
CYP3A4 P08684 2/20 0.38
CYP17A1 P05093 1/20 0.37
CYP11B1 P15538 1/20 0.37
BCHE P06276 2/20 0.37
KDM4E B2RXH2 1/20 0.37
DYRK3 O43781 1/20 0.37
CCNT1 O60563 1/20 0.37
CCNB2 O95067 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664204 1.00 DYRK1A (0.58) DYRK1AENPP1ENPP3CYP19A1NT5E
SCHEMBL29756312 0.84 MAOA (0.54) DYRK1ACYP19A1GCGRMAPK14CHUK
SCHEMBL20122797 0.84 MAOA (0.54) DYRK1ACYP19A1GCGRMAPK14CHUK
SCHEMBL30664183 0.81 DYRK1A (0.48) DYRK1ACYP19A1GCGRMAPK14CHUK
SCHEMBL20122796 0.81 DYRK1A (0.48) DYRK1ACYP19A1GCGRMAPK14CHUK
SCHEMBL30664161 0.78 MAOA (0.43) DYRK1ACYP3A4KDM4EDYRK3CCNT1
SCHEMBL20122850 0.78 MAOA (0.43) DYRK1ACYP3A4KDM4EDYRK3CCNT1
SCHEMBL20123067 0.76 CCNB2 (0.40) DYRK1ACHUKCYP3A4BCHEKDM4E
SCHEMBL30664150 0.76 CCNB2 (0.40) DYRK1ACHUKCYP3A4BCHEKDM4E
SCHEMBL20122946 0.74 CHUK (0.61) DYRK1AGCGRMAPK14CHUKICOSLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885ENPP1 2366/4885ENPP3 2016/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885ENPP1 2366/4885ENPP3 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.